Dianthus Therapeutics (DNTH) to Release Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is anticipated to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Dianthus Therapeutics to post earnings of ($0.88) per share and revenue of $0.5760 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Stock Performance

DNTH opened at $34.03 on Tuesday. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $40.16. The stock has a market capitalization of $1.10 billion, a P/E ratio of -10.47 and a beta of 1.56. The business’s 50-day simple moving average is $33.79 and its 200-day simple moving average is $24.71.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DNTH shares. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Robert W. Baird raised their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 9th. Guggenheim upped their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Finally, Wedbush increased their target price on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $60.88.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.56% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at approximately $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Dianthus Therapeutics by 31.1% in the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after buying an additional 4,962 shares in the last quarter. Finally, Rafferty Asset Management LLC grew its holdings in Dianthus Therapeutics by 19.5% during the second quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company’s stock worth $531,000 after acquiring an additional 4,650 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.